KRAS and neoplasm: In this cohort, 38% of KRAS wild-type tumours harboured other alterations with the potential to activate the Receptor Tyrosine Kinase (RTK)/Ras/MAP Kinase (MAPK) signalling pathway, suggesting that more careful selection of patients who may respond to EGFR inhibitor therapy is required beyond KRAS alone.